Difelikefalin not checked

Vifor Fresenius Medical Care Renal Pharma · Cara Therapeutics, Inc. · MR13A9 · CR845

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 2 trial completes
Trials
1 active
12 in total · 1 in the EU

What this is

How it works
Kappa Opioid Receptor Agonist FDA class
How it’s given
“The study includes a screening period of up to 4 weeks (including a 7-day run-in period during the week prior to enrolment), a study treatment period of 12 weeks, and a safety follow-up visit at 7 (up to 10) days after EoT. Total study duration for a single participant is up to 17 to 18 weeks.”In the company’s words, NCT06593392 on ClinicalTrials.gov
Tested for
Pruritus, Chronic Kidney Diseases
Main trialPhase 2
“Rationale: * People with long term kidney disease who are on haemodialysis (a procedure for removing waste products from the blood) commonly develop a condition that makes their skin very itchy. * Difelikefalin is a medicine that can treat the itching related to long term kidney disease. * Clinical studies have shown difelikefalin to reduce itching in adults on haemodialysis, while being safe and tolerable. * The current study is being done in adolescents aged 12 to 17 years on haemodialysis who have moderate to severe itching related to long term kidney disease to assess if difelikefalin is…”In the company’s words, NCT06593392 on ClinicalTrials.gov
Other names
MR13A9 · CR845

Other drugs for Pruritus

All 16 drugs for Pruritus

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials12

TrialPhaseCompletesWhat it tests
Phase 2Recruiting 15 Aug 2029 Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus
Phase 3Completed 6 Apr 2019 A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)
Phase 3Completed 11 Feb 2020 Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
Phase 3Completed 26 Feb 2020 CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
Phase 3Completed 30 Mar 2020 CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
Phase 3Completed 25 Jan 2022 A Phase III Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.
Phase 3Completed 25 Sep 2024 Phase 3 Study of Difelikefalin in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus
Phase 2Completed 22 Oct 2019 A Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.
Phase 2Completed 24 Oct 2019 A Study to Evaluate the Safety and Efficacy of CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus
Phase 2Terminated 29 Jun 2022 Study to Evaluate the Safety and Efficacy of Oral CR845 (Difelikefalin) in Patients With Primary Biliary Cholangitis (PBC) and Moderate-to-Severe Pruritus
Phase 1Completed 11 Jun 2020 CR845-100303: Study to Assess the Potential of Physical Withdrawal From Intravenous CR845 (Difelikefalin) in Hemodialysis Patients
Phase 1Completed 9 Oct 2023 Pharmacokinetics of Intravenous Difelikefalin in Chinese Adult Subjects on Haemodialysis
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Difelikefalin

Following is part of Solo: you see every change to Difelikefalin the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in